(0.38%) 5 125.75 points
(0.15%) 38 786 points
(0.72%) 17 734 points
(0.20%) $83.53
(-0.44%) $1.804
(-0.10%) $2 339.80
(0.12%) $27.40
(0.27%) $925.30
(0.03%) $0.934
(-0.05%) $10.90
(0.00%) $0.803
(-0.17%) $93.03
Live Chart Being Loaded With Signals
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe...
Stats | |
---|---|
Today's Volume | 0 |
Average Volume | 0 |
Market Cap | 0 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Dynavax Technologies Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dynavax Technologies Financials
Annual | 2020 |
Revenue: | $46.55M |
Gross Profit: | $32.64M (70.12 %) |
EPS: | $-0.750 |
Q3 | 2021 |
Revenue: | $108.27M |
Gross Profit: | $48.18M (44.50 %) |
EPS: | $-0.240 |
Q2 | 2021 |
Revenue: | $52.77M |
Gross Profit: | $37.92M (71.87 %) |
EPS: | $0 |
Q4 | 2020 |
Revenue: | $46.55M |
Gross Profit: | $32.64M (70.12 %) |
EPS: | $-0.750 |
Financial Reports:
No articles found.
Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators